Radiation Therapy and Nivolumab with Relatlimab-rmbw Achieved a Complete Response in Metastatic Cutaneous Melanoma to the Orbit
We present a patient with left orbital metastasis of cutaneous melanoma, treated with 30 Gy in 10 fraction radiation therapy followed by a combination of programmed death-1 inhibitor, nivolumab, and lymphocyte-activation gene inhibitor, relatlimab. The patient achieved a complete response to treatment, with no evidence of recurrence of the orbital mass, 17 months after treatment initiation.
Authors
- Devarati Mitra (ORCID: https://orcid.org/0000-0002-2225-164X)
- Kim O. Learned (ORCID: https://orcid.org/0000-0002-5125-4022)
- Oded Sagiv (ORCID: https://orcid.org/0000-0003-0563-278X)
- Amina L. Chaudhry
- Brandon T. Sellers
Institutions
- The University of Texas MD Anderson Cancer Center (US)
- San Antonio Uniformed Services Health Education Consortium (US)
Publication Details
- Journal
- Ophthalmic Plastic and Reconstructive Surgery
- Published
- 2026-01-12
- DOI
- https://doi.org/10.1097/iop.0000000000003162
- Primary Topic
- Ocular Oncology and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00